Cargando…
Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
INTRODUCTION: Intraocular inflammation (IOI)-related adverse events (AEs) that may result in severe vision loss have been associated with the anti-vascular endothelial growth factor brolucizumab. In this study, we investigate the timing, management and resolution of IOI-related AEs in a large cohort...
Autores principales: | Zubricky, Ryan, McCoy, Jasmyne, Donkor, Richard, Miller, David G., Sonbolian, Nina, Heaney, Andrew, Bilano, Ver, Karcher, Helene, Coney, Joseph M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442012/ https://www.ncbi.nlm.nih.gov/pubmed/37310683 http://dx.doi.org/10.1007/s40123-023-00741-w |
Ejemplares similares
-
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration
por: Coney, Joseph M., et al.
Publicado: (2023) -
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
por: Coney, Joseph M, et al.
Publicado: (2023) -
Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023) -
Brolucizumab for macular degeneration
Publicado: (2020) -
Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis
por: Finger, Robert P., et al.
Publicado: (2022)